DiaMedica Therapeutics
DMAC
36 hedge funds and large institutions have $11M invested in DiaMedica Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 2 closing their positions.
813% more call options, than puts
Call options by funds: $73K | Put options by funds: $8K
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
13% more funds holding
Funds holding: 32 → 36 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.76% less ownership
Funds ownership: 12.96% → 11.2% (-1.8%)
27% less capital invested
Capital invested by funds: $15.1M → $11M (-$4.11M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$1.59M |
| 2 |
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Dallas,
Texas
|
+$466K |
| 3 |
AC
Aristides Capital
Louisville,
Kentucky
|
+$342K |
| 4 |
Morgan Stanley
New York
|
+$118K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bleichroeder LP
New York
|
-$231K |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$186K |
| 3 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
-$96.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$73.1K |
| 5 |
First Manhattan
New York
|
-$32.1K |
DMAC Hedge Fund Activity: Q3 2023 in Review
36 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q3 2023, worth a combined $11M — down 27% from $15.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DMAC positions and 2 closed out — a net gain of 4 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $1.59M. The largest seller was Bleichroeder LP, cutting an estimated $231K.
- 36 institutional investors held DiaMedica Therapeutics (DMAC) as of Q3 2023, up from 32 in Q2 2023.
- Funds reported $11M of DiaMedica Therapeutics stock for Q3 2023, down 27% quarter-over-quarter.
- 6 funds opened new DiaMedica Therapeutics positions in Q3 2023 and 2 closed out, a net change of +4 holders.
- The largest DiaMedica Therapeutics buyer in Q3 2023 was Altium Capital Management, an estimated $1.59M added.
- The largest DiaMedica Therapeutics seller in Q3 2023 was Bleichroeder LP, an estimated $231K sold.
Based on aggregated 13F filings for Q3 2023.